Financial Performance - Core sales increased by 6% CER to $532 million, exceeding the outlook of ≥5%[5,9] - Net sales reached $533 million, a 5% CER increase compared to Q3 2024[5,7] - Adjusted diluted EPS was $0.61 CER, a 7% CER increase, surpassing the outlook of ≥$0.58 CER[5] - Adjusted operating income margin remained steady at 29.6%[5,24] - Operating cash flow for 9M 2025 was $466 million, a 3% decrease[5] Product and Portfolio Developments - QIAstat-Dx and QuantiFERON both experienced 11% CER growth, leading the portfolio[5,8] - Sample technologies showed a 3% CER growth[5,8] - QIAcuity digital PCR and QDI delivered solid contributions[5,8] - Parse Biosciences acquisition is expected to contribute ~$40 million in sales in 2026[22] Outlook and Capital Allocation - The company reaffirmed its 2025 net sales outlook of +4-5% CER (+5-6% CER core growth)[5] - The company increased its adjusted diluted EPS outlook to ~$2.38 CER (previously ~$2.35 CER)[5] - At least $1 billion of returns to shareholders is planned for 2024-28 (absent M&A)[14] - $500 million share repurchase program is authorized for completion in January 2026[15]

Financial Performance - Net sales reached $534 million, a 6% increase CER (constant exchange rate) compared to Q2 2024[5] - Core sales also grew by 6% CER[5] - Adjusted diluted EPS was $062 CER, exceeding the outlook of ≥$060 CER[5] - Adjusted operating income margin improved by 15 percentage points to 299% compared to Q2 2024[5] - H1 2025 operating cash flow remained steady at $301 million compared to H1 2024[5] Product and Portfolio Developments - QIAstat-Dx led growth with a 41% CER increase[5, 8] - QuantiFERON also showed strong performance with an 11% CER growth[5, 8] - Sample technologies, QIAcuity digital PCR, and QDI contributed to overall growth[5] Outlook - The company increased its 2025 net sales outlook to +4-5% CER (+5-6% CER core growth)[5] - Adjusted diluted EPS outlook is reaffirmed at approximately $235 CER[5] - Adjusted operating income margin target is set at approximately 30%[5] Capital Allocation - The company plans to return at least $1 billion to shareholders between 2024 and 2028, absent M&A activity[23] - The first-ever annual dividend payment of $54 million was paid in July 2025[23] - Authorization for synthetic share repurchase of up to $500 million over 18 months[24]